Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Depression in Parkinson's disease.

D J Burn1

  • 1Regional Neurosciences Centre, Newcastle General Hospital, Newcastle upon Tyne, UK. d.j.burn@ncl.ac.uk

European Journal of Neurology
|December 5, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Trajectories of pain over 6 years in early Parkinson's disease: ICICLE-PD.

Journal of neurology·2021
Same author

Progression of Neuropsychiatric Symptoms over Time in an Incident Parkinson's Disease Cohort (ICICLE-PD).

Brain sciences·2020
Same author

Prevalence and duration of non-motor symptoms in prodromal Parkinson's disease.

European journal of neurology·2019
Same author

Cerebral glucose metabolism and cognition in newly diagnosed Parkinson's disease: ICICLE-PD study.

Journal of neurology, neurosurgery, and psychiatry·2017
Same author

Cognitive impairment in Parkinson's disease: impact on quality of life of carers.

International journal of geriatric psychiatry·2016
Same author

Short latency afferent inhibition: Effects of ageing.

Clinical neurophysiology : official journal of the International Federation of Clinical Neurophysiology·2016
Same journal

Blood Pressure Control With Clevidipine Is Associated With Hematoma Volume Reduction in Acute Hypertensive Intracerebral Hemorrhage: A Single-Center Prospective Cohort Study.

European journal of neurology·2026
Same journal

CGRP-Targeted Therapy in Vestibular Migraine-How Strong Is the Evidence?

European journal of neurology·2026
Same journal

Direct Thrombectomy vs. Combined Treatment With Intravenous Thrombolysis in the Extended Time Window: A Target Trial Emulation.

European journal of neurology·2026
Same journal

Pharmacological Treatment of Cerebellar Ataxia in Pediatric Ataxia-Telangiectasia: A Systematic Review.

European journal of neurology·2026
Same journal

Intensive Rehabilitation With Adjunctive Bilateral Anodal tDCS in Post-Stroke Dysphagia: A Multicenter Randomized Controlled Trial.

European journal of neurology·2026
Same journal

Distal Agrin (AGRN) Congenital Myasthenic Syndrome With Mitochondrial Dysfunction.

European journal of neurology·2026
See all related articles

Depression is a common Parkinson's disease (PD) complication impacting quality of life. Early recognition and treatment of depression in PD patients are crucial for managing motor and cognitive functions.

Area of Science:

  • Neurology
  • Psychiatry
  • Pharmacology

Background:

  • Depression is a frequent complication of Parkinson's disease (PD), significantly affecting patient quality of life.
  • Untreated depression in PD can lead to premature cessation of antiparkinsonian therapies.
  • The reported prevalence of depression in PD varies widely (2.7–70%) due to methodological differences.

Purpose of the Study:

  • To review the complex etiology of depression in Parkinson's disease.
  • To discuss diagnostic tools and current treatment strategies for depression in PD.
  • To highlight the association between depression and disease progression in PD.

Main Methods:

  • Literature review focusing on the pathophysiology, diagnosis, and treatment of depression in Parkinson's disease.

Related Experiment Videos

  • Analysis of existing diagnostic scales like the Montgomery-Asberg Depression Rating Scale and Hamilton Rating Scale for Depression.
  • Evaluation of current pharmacological approaches, including dopaminergic drugs and selective serotonin reuptake inhibitors.

    • Main Results:

    • Depression in PD has complex tonic and phasic components, potentially preceding motor symptoms.
    • Hedonistic homeostatic dysregulation is a mood disorder linked to dopaminergic therapy.
    • Selective serotonin reuptake inhibitors are the primary antidepressants used for PD patients, despite limited large-scale studies.

    Conclusions:

    • Depression in Parkinson's disease is multifactorial and requires careful management.
    • Accurate diagnosis using validated scales is essential.
    • Depression may accelerate cognitive and motor decline in PD patients, necessitating integrated treatment approaches.